<DOC>
	<DOCNO>NCT01160796</DOCNO>
	<brief_summary>This national , multi-centre , randomize , double-blind placebo-controlled , phase III superiority trial . The main objective trial ass efficacy Lcr35® compare mean time onset first clinical recurrence confirm laboratory test patient bacterial vaginosis treat Lcr35® versus placebo . Patients bacterial vaginosis enroll private gynecologist . Each patient receive treatment initial episode ( Metronidazole ) treatment prevent recurrence bacterial vaginosis ( Lcr35® ) .</brief_summary>
	<brief_title>Lcr35® Bacterial Vaginosis Prevention</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Patient present symptomatic vaginosis characterise presence follow 3 clinical criterion ( among 4 Amsel criterion ) V1 : greyish uniform vaginal discharge , characteristic `` rotten fish '' smell cause spontaneous release amine potassium test `` sniff test '' , vaginal pH great 4.5 . Patient Nugent score ≥ 7 ( use sample take V1 ) . Patient clinically cure ( none 3 Amsel criterion ) 7day course Metronidazole ( Flagyl® ) Female . Patient 18 year age . For woman childbearing potential : negative urine pregnancy test , use contraceptive method deem effective Investigator ( exclude spermicide ) . Patient receive information voluntarily sign write Informed Consent Form . Patient cover national insurance scheme . Presence yeast infection bacterial ( vaginosis ) viral origin presume proven gynaecologicallylinked , whether treat within month precede inclusion present time inclusion . Presence exist gynaecological infection may interfere assessment trial treatment ( fibroma , severe dysplasia cervix situ carcinoma , invasive carcinoma , intraepithelial cervical neoplasia , squamous intraepithelial lesion etc . ) Antibiotics antifungal take general route month precede screen visit , exclude treatment earlier episode vaginosis . Use probiotic month precede screen visit , exclude treatment earlier episode vaginosis . Use intravaginal antiseptic month precede screen visit , exclude treatment earlier episode vaginosis . Use prebiotics ( acidifiers ) two week precede screen visit . Use product contain topical oestrogen month precede screen visit . Allergy one active ingredient one excipients product . patient postmenopausal time Patient unable comply constraint Protocol . Breastfeeding patient . Patient menstrual bleeds last 12 day month . Patient take part clinical trial 3 month precede inclusion present Protocol . Patient severe acute chronic disease deem Investigator incompatible participation trial , serious infection lifethreatening short term . Immunosuppressed patient . Patient present previous illness , accord Investigator , likely interfere result trial expose patient additional risk . Patient linguistically mentally unable understand sign Informed Consent Form . Patient deprive liberty order Courts civil authority subject guardianship order . Patient likely comply treatment . Patient unable contact case emergency .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>